Agilent Technologies Introduces AdvanceBio Peptide Mapping Columns
New HPLC and HILIC Solutions Enable Faster, More Robust Analysis in Biopharmaceutical Discovery
SANTA CLARA, Calif., May 13, 2013
Agilent Technologies Inc. (NYSE: A) today introduced the latest updates to its AdvanceBio family of columns. The new AdvanceBio Peptide Mapping BioHPLC and ZORBAX RRHD 300-HILIC columns are designed to deliver exceptional performance for the separation, characterization and analysis of a wide range of proteins, monoclonal antibodies, peptides and additional biologics.
Each of these columns enables users to achieve the highest-resolution results, faster than ever before.
"We are excited to introduce these valuable new columns to our pharmaceutical customers and other life science researchers seeking ever-greater analytical sensitivity and speed," said Anne Jones, Agilent's vice president and general manager for the chemistries business. "These products are an example of our ongoing commitment to advancing accuracy and productivity in biochromatography."
The new AdvanceBio Peptide Mapping column can rapidly determine the primary protein structure and identify modifications with unparalleled speed and sensitivity. In fact, it can produce exceptional analytical results two to three times faster than conventional peptide mapping with fully porous HPLC columns, which can take up to 60 minutes.
Each batch of AdvanceBio mapping media is tested with a rigorous peptide mix to ensure suitability and reproducibility, enabling the identification of key peptides in complex peptide maps. All available columns are stable to 600-bar, enabling maximum UHPLC instrument performance. They also deliver exceptional performance with legacy 400-bar instruments.
The AdvanceBio Peptide Mapping column is excellent for highly complex peptide mapping and will provide 100 percent sequence coverage of many protein digests, including rhEPO with 45 glycopeptide matches. These features are explored in the application note, High-Resolution Glycopeptide Mapping of EPO Using an Agilent AdvanceBio Peptide Mapping Column.
The ZORBAX RRHD 300-HILIC columns are the only sub 2-µm, 300Å HILIC columns available today. They are designed specifically for users seeking faster, higher-resolution separation of peptides, polar glycopeptides, proteins, antibodies, conjugates, new biological entities and biopharmaceuticals.
Hydrophilic interaction liquid chromatography is designed to resolve hydrophilic glycopeptide variants. It also provides excellent peak shape for polar glycopeptides that have limited retention and resolution with reversed-phased columns. For 1.8 µm particles, the ZORBAX RRHD 300-HILIC columns enable rapid analysis and 1200-bar stability with exceptional accuracy. They provide orthogonal and complementary separations to reversed-phase HPLC. These features are explored in the application note, Analysis of Erythropoietin Glycopeptides and Glycoforms by HILIC and RP Chromatography.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.
# # #
For images related to this press release,
please visit the ImageLibrary (Image #12 & #13)
+1 408 553 7093